Agilex Biolabs, Australia's largest specialist bioanalytical laboratory for biotech clinical trials, is presenting the
Australian Advantage including the world's most attractive rebate on clinical trials costs, at BIO Korea 2020.
The presentation by Kurt Sales (B.Sc; B.Sc (MED) Hons; M.Sc, Ph.D, PGCM)
Director, Immunoassay at Agilex Biolabs, also detailed how well the Australian clinical trials industry had managed
during the COVID-19 crisis with most sites, CROs, and labs including Agilex Biolabs, staying open.
The presentation is at 13.50 on Friday 22, May 2020 via the virtual conference platform. https://www.biokorea.org/index.asp
Agilex Biolabs also launched a News Video Update on the COVID-19 impact on clinical trials in Australia. Watch here. https://youtu.be/vZuHAYZ-GiE
Agilex Biolabs specializes in bioanalysis of small molecules and biologics for PK, immunogenicity, biomarkers and
immunological pharmacodynamics assessments.
Agilex Biolabs, the only FDA-inspected lab of its type in the region, is located in Adelaide, South Australia in a
science and biotech specialist hub.
Agilex Biolabs CEO Jason Valentine said: "Aglilex Biolabs has just expand its labs by more than 30% to accommodate
biotech demand from APAC and the USA."
He said more than 38% of Agilex Biolabs' biotech clients already come from the APAC region - primarily from China and
South Korea.
"APAC clients are particularly attracted by Agilex Biolabs' FDA-inspected status, and the more than 40% rebate on
clinical trial spend that applies in Australia," he said.
"Our world-class bioanalytical facilities have OECD GLP Recognition with NATA (Australian Government OECD GLP Compliance
monitoring authority) and ISO 17025 Accreditation for global recognition."
Agilex Biolabs specialises in bioanalysis of small molecules and biologics for PK, immunogenicity, biomarkers and
immunological pharmacodynamics assessments utilising LC-MS/MS, immunoassay (Mesoscale, Gurolab, Luminex) and flow
cytometry (BD FACSymphony A3, 20 colour cell analyser).
Agilex also offers pharmacodynamics services that include immunobiology services using the latest state-of-the-art
technology to support immunology, cell biology and mode of action assays, including:ImmunophenotypingReceptor occupancyCytokine release assays (whole blood or PBMC stimulation assays) and cytokine/biomarker profilingPBMC assays and cellular mechanism of action assays (eg: ADCC)
The FDA-inspected facilities have more than 65 dedicated laboratory staff, and annually support more than 80 clinical
trials. This year they will analyse more than 60,000 samples for pharma/biotechs from US, Europe and APAC.